- Report
- March 2024
- 181 Pages
Global
From €3259EUR$3,374USD£2,787GBP
€3621EUR$3,749USD£3,097GBP
- Report
- May 2024
- 93 Pages
Global
From €5409EUR$5,600USD£4,626GBP
- Report
- November 2023
- 145 Pages
Global
From €2414EUR$2,499USD£2,064GBP
- Report
- November 2023
- 182 Pages
Global
From €4733EUR$4,900USD£4,047GBP
- Report
- February 2024
- 200 Pages
Global
From €3864EUR$4,000USD£3,304GBP
- Report
- January 2022
- 120 Pages
Global
From €2415EUR$2,500USD£2,065GBP
- Report
- August 2022
- 123 Pages
Global
From €4588EUR$4,750USD£3,923GBP
- Report
- June 2020
- 62 Pages
France
From €4588EUR$4,750USD£3,923GBP
- Report
- March 2024
- 79 Pages
Global
From €3500EUR$3,881USD£3,098GBP
- Book
- September 2019
- 512 Pages
- Book
- January 2014
- 472 Pages
- Book
- May 2013
- 352 Pages
Canada, Global
Canine Atopic Dermatitis (CAD) is a common skin condition in dogs that is caused by an allergic reaction to environmental allergens such as pollen, dust mites, and mold. Symptoms of CAD include itching, redness, and hair loss. Treatment of CAD typically involves the use of anti-inflammatory medications, topical treatments, and allergen-specific immunotherapy.
The Animal Healthcare/Veterinary market for CAD is growing as pet owners become more aware of the condition and its treatments. Veterinary clinics are increasingly offering CAD treatments, and the market for CAD treatments is expected to continue to grow.
Companies in the Canine Atopic Dermatitis market include Zoetis, Merck Animal Health, Elanco Animal Health, and Bayer Animal Health. Show Less Read more